Should You Buy AstraZeneca plc, WH Smith Plc & De La Rue plc Today?

Royston Wild considers the investment case for AstraZeneca plc (LON: AZN), WH Smith Plc (LON: SMWH) and De La Rue plc (LON: DLAR).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m running the rule over three recent headline makers.

Book beauty

Stationery and magazines giant WH Smith (LSE: SMWH) has fallen 3% following its latest trading update released today. But I view this as nothing more than profit-taking following the share’s steady price ascent.

The retailer — which recently struck record peaks of 1,878p per share — advised that pre-tax profit surged 11% in the six months to February, to £80m. Although like-for-like sales at its High Street division were flat, this represented WH Smith’s best performance for years.

The impact of massive cost-cutting, coupled with huge investment in new products in recent years, is clearly paying off handsomely. And I reckon the stationer’s rolling store expansion scheme should also keep profits heading higher in the years ahead.

This view is shared by the City, and WH Smith is expected to print earnings rises of 7% and 8% for the years to August 2016 and 2017, respectively. I reckon subsequent P/E ratings of 19.2 times and 18 times are fair value given the exceptional progress of WH Smith’s turnaround strategy.

Time to cash out?

Like WH Smith, De La Rue (LSE: DLAR) also released bubbly trading numbers in midweek trading. But these better-than-expected results drove shares in the cash printer 10% higher from Tuesday’s close.

De La Rue announced that revenue for the period to March 2016 had been in line with expectations, adding that full-year underlying operating profit is now expected to ring in at £62m, beating its previous estimates. The company attributed this upgrade to the “strong operational outperformance on certain contracts within our Currency business.”

Despite today’s positive news, however, I believe that De La Rue remains a risky selection for stock pickers thanks to the impact of rising competition, and the potential for increasing revenue troubles in an increasingly ‘cashless’ world.

The City expects De La Rue to bounce from a 27% earnings slip in fiscal 2016 with an 11% bump next year. Some would argue that low P/E ratings of 13.2 times and 11.7 times fairly reflect the risks facing the money-maker. But I reckon the huge structural issues facing the firm still make it an unattractive stock selection.

Sales outlook still improving

A string of positive testing news has boosted the revenues picture for drugs giant AstraZeneca (LSE: AZN) in recent days.

The Cambridge firm received positive news yesterday after Clovis Oncology‘s lung cancer battler Rociletinib had been shot down by the US Food and Drug Administration. The news paves the way for AstraZeneca’s own Tagrisso treatment to dominate the market, the drug having received approval in the autumn.

AstraZeneca’s renewed efforts to rejuvenate its product pipeline are clearly producing the goods, with it also announcing this week that its Alzheimer’s product designed with Eli Lilly will proceed to Phase III testing.

Sure, the issue of patent expirations on key drugs is expected to keep earnings under pressure for some time yet — bottom line dips of 7% and 1% are currently pencilled-in by the City for 2016 and 2017, respectively. Still, I reckon consequent P/E ratios of 14.8 times and 15 times represent terrific entry points to get on board AstraZeneca’s ever-improving long-term outlook.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »